As a pharmaceutical manufacturer, how well do you achieve consistent product with the required particle size distribution (PSD)? How effective are your advanced process control schemes? Such consistency typically requires experiment…after experiment…after experiment, as well as substantial active pharmaceutical ingredient (API) consumption during development.

In this case study, we collaborated with the ADDoPT project to develop a novel approach using a model as a digital twin for in-silico model predictive control (MPC) development. The proposed advanced control scheme required up to 60% fewer trials, resulting in substantially reduced API consumption and experimental effort.

For details on our approach and methods, check out the full use case below.

Share this Page

Related Posts

The Data Scientist Conundrum

Making best use of Data Scientist skills relies on integrated end-to-end software solution

Fast Track New Vaccines to Market

Move confidently into efficient vaccine manufacturing with a proven advanced process control platform

Improve yield learning and accelerate yield ramp

Improve Yield Learning And Accelerate
Building a quality ecosystem in your fab with pre-integrated SmartFactory Yield and Defect Management solutions